Loading…

Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice

Aims/hypothesis AGEs are involved in diabetic complications and might be responsible for the phenomenon of ‘hyperglycaemic memory’. d -Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in Apoe -null mice. This study aimed to v...

Full description

Saved in:
Bibliographic Details
Published in:Diabetologia 2015-04, Vol.58 (4), p.845-853
Main Authors: Menini, Stefano, Iacobini, Carla, Ricci, Carlo, Fantauzzi, Claudia Blasetti, Pugliese, Giuseppe
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523
cites cdi_FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523
container_end_page 853
container_issue 4
container_start_page 845
container_title Diabetologia
container_volume 58
creator Menini, Stefano
Iacobini, Carla
Ricci, Carlo
Fantauzzi, Claudia Blasetti
Pugliese, Giuseppe
description Aims/hypothesis AGEs are involved in diabetic complications and might be responsible for the phenomenon of ‘hyperglycaemic memory’. d -Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in Apoe -null mice. This study aimed to verify the protective effect of DCO in atherosclerosis and renal disease induced by experimental diabetes and to discover whether reduction of AGE formation by early vs late DCO treatment provides better macro and microvascular protection. Methods Apoe -null mice were rendered diabetic by streptozotocin and were left untreated or were treated with DCO for 20 weeks (DCO-Extended), from week 1 to 11 (DCO-Early) or from week 9 to 19 (DCO-Late). Non-diabetic Apoe -null mice served as controls. Aortic and renal lesions were evaluated by morphometry and protein and gene expression of disease markers were assessed by immunohistochemistry and real-time PCR. Results DCO-Extended treatment produced a more stable plaque phenotype by markedly attenuating diabetes-induced increases in lesion size, necrotic core area and plaque content of Nε-carboxymethyllysine, levels of apoptotic cells and markers of inflammation and oxidative stress and also reductions in collagen and smooth muscle cells. DCO treatment for 11 weeks afforded partial protection and this was significantly better in DCO-Early mice than in DCO-Late mice. Renal disease was attenuated in DCO-Extended mice and to a lesser extent in those treated for 11 weeks, with no significant difference between DCO-Early mice and DCO-Late mice. Conclusions/interpretation These data show that DCO protects mice from diabetes-induced vascular and renal disease and that protection against atherosclerosis is more effectively achieved by early treatment than by late treatment, thus suggesting that early inhibition of AGE formation attenuates progression of macroangiopathy and favours development of more stable lesions.
doi_str_mv 10.1007/s00125-014-3467-6
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1661330914</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1661330914</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523</originalsourceid><addsrcrecordid>eNp1kcGKFDEQhoMo7uzoA3iRgBcv0aSTTme8LYu6woIeFLw11UllN0smPSbdC_1iPp_pmVVE8JJA_q_-qtRPyAvB3wjOu7eFc9G0jAvFpNId04_IRijZMK4a85hsVpkJo7-fkfNS7jjnslX6KTlrWtWJbqc25OeXPE5opzAm6vO4py7AgBMWFpKbLToK0y3msdi4nqFQSI5mTBArWhAK0mGhjlnIqeoJ2WinJWKZML-j6H01L3T0FCHHhd4XGmFCGtJtGMKxbdXA3UNam93ExcLxFZNjhzzWGWp5SPTiMCJLc4x0Hyw-I088xILPH-4t-fbh_dfLK3b9-eOny4trZpVpJ9Z5oTQK6IzfDQASrbHWt61ELb20jTADgrXCeNcoI73znTLWA6BttGkbuSWvT751lB9z_VS_D8VijJBwnEsvtBZS8l3d-pa8-ge9G-dc93SkuDFadaZS4kTZus2S0feHHPaQl17wfg21P4Xa11D7NdRe15qXD87zsEf3p-J3ihVoTkCpUrrB_Ffr_7r-AoYAsbM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1660886478</pqid></control><display><type>article</type><title>Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice</title><source>Springer Nature</source><creator>Menini, Stefano ; Iacobini, Carla ; Ricci, Carlo ; Fantauzzi, Claudia Blasetti ; Pugliese, Giuseppe</creator><creatorcontrib>Menini, Stefano ; Iacobini, Carla ; Ricci, Carlo ; Fantauzzi, Claudia Blasetti ; Pugliese, Giuseppe</creatorcontrib><description>Aims/hypothesis AGEs are involved in diabetic complications and might be responsible for the phenomenon of ‘hyperglycaemic memory’. d -Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in Apoe -null mice. This study aimed to verify the protective effect of DCO in atherosclerosis and renal disease induced by experimental diabetes and to discover whether reduction of AGE formation by early vs late DCO treatment provides better macro and microvascular protection. Methods Apoe -null mice were rendered diabetic by streptozotocin and were left untreated or were treated with DCO for 20 weeks (DCO-Extended), from week 1 to 11 (DCO-Early) or from week 9 to 19 (DCO-Late). Non-diabetic Apoe -null mice served as controls. Aortic and renal lesions were evaluated by morphometry and protein and gene expression of disease markers were assessed by immunohistochemistry and real-time PCR. Results DCO-Extended treatment produced a more stable plaque phenotype by markedly attenuating diabetes-induced increases in lesion size, necrotic core area and plaque content of Nε-carboxymethyllysine, levels of apoptotic cells and markers of inflammation and oxidative stress and also reductions in collagen and smooth muscle cells. DCO treatment for 11 weeks afforded partial protection and this was significantly better in DCO-Early mice than in DCO-Late mice. Renal disease was attenuated in DCO-Extended mice and to a lesser extent in those treated for 11 weeks, with no significant difference between DCO-Early mice and DCO-Late mice. Conclusions/interpretation These data show that DCO protects mice from diabetes-induced vascular and renal disease and that protection against atherosclerosis is more effectively achieved by early treatment than by late treatment, thus suggesting that early inhibition of AGE formation attenuates progression of macroangiopathy and favours development of more stable lesions.</description><identifier>ISSN: 0012-186X</identifier><identifier>EISSN: 1432-0428</identifier><identifier>DOI: 10.1007/s00125-014-3467-6</identifier><identifier>PMID: 25471794</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject><![CDATA[Age ; Animals ; Aorta - drug effects ; Aorta - metabolism ; Aorta - pathology ; Aortic Diseases - blood ; Aortic Diseases - diagnosis ; Aortic Diseases - genetics ; Aortic Diseases - prevention & control ; Apolipoproteins E - deficiency ; Apolipoproteins E - genetics ; Atherosclerosis ; Atherosclerosis - blood ; Atherosclerosis - diagnosis ; Atherosclerosis - genetics ; Atherosclerosis - prevention & control ; Biomarkers - blood ; Carnosine - analogs & derivatives ; Carnosine - pharmacology ; Diabetes ; Diabetes Mellitus, Experimental - blood ; Diabetes Mellitus, Experimental - diagnosis ; Diabetes Mellitus, Experimental - drug therapy ; Diabetes Mellitus, Experimental - genetics ; Diabetic Angiopathies - blood ; Diabetic Angiopathies - diagnosis ; Diabetic Angiopathies - genetics ; Diabetic Angiopathies - prevention & control ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - diagnosis ; Diabetic Nephropathies - genetics ; Diabetic Nephropathies - prevention & control ; Disease Progression ; Epidemiology ; Female ; Glycation End Products, Advanced - antagonists & inhibitors ; Glycation End Products, Advanced - blood ; Human Physiology ; Hyperglycemia ; Internal Medicine ; Kidney - drug effects ; Kidney - metabolism ; Kidney - pathology ; Kidney diseases ; Laboratory animals ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Metabolism ; Mice ; Mice, Knockout ; Plaque, Atherosclerotic ; Signal Transduction - drug effects ; Smooth muscle ; Time Factors]]></subject><ispartof>Diabetologia, 2015-04, Vol.58 (4), p.845-853</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>Springer-Verlag Berlin Heidelberg 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523</citedby><cites>FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25471794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Menini, Stefano</creatorcontrib><creatorcontrib>Iacobini, Carla</creatorcontrib><creatorcontrib>Ricci, Carlo</creatorcontrib><creatorcontrib>Fantauzzi, Claudia Blasetti</creatorcontrib><creatorcontrib>Pugliese, Giuseppe</creatorcontrib><title>Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice</title><title>Diabetologia</title><addtitle>Diabetologia</addtitle><addtitle>Diabetologia</addtitle><description>Aims/hypothesis AGEs are involved in diabetic complications and might be responsible for the phenomenon of ‘hyperglycaemic memory’. d -Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in Apoe -null mice. This study aimed to verify the protective effect of DCO in atherosclerosis and renal disease induced by experimental diabetes and to discover whether reduction of AGE formation by early vs late DCO treatment provides better macro and microvascular protection. Methods Apoe -null mice were rendered diabetic by streptozotocin and were left untreated or were treated with DCO for 20 weeks (DCO-Extended), from week 1 to 11 (DCO-Early) or from week 9 to 19 (DCO-Late). Non-diabetic Apoe -null mice served as controls. Aortic and renal lesions were evaluated by morphometry and protein and gene expression of disease markers were assessed by immunohistochemistry and real-time PCR. Results DCO-Extended treatment produced a more stable plaque phenotype by markedly attenuating diabetes-induced increases in lesion size, necrotic core area and plaque content of Nε-carboxymethyllysine, levels of apoptotic cells and markers of inflammation and oxidative stress and also reductions in collagen and smooth muscle cells. DCO treatment for 11 weeks afforded partial protection and this was significantly better in DCO-Early mice than in DCO-Late mice. Renal disease was attenuated in DCO-Extended mice and to a lesser extent in those treated for 11 weeks, with no significant difference between DCO-Early mice and DCO-Late mice. Conclusions/interpretation These data show that DCO protects mice from diabetes-induced vascular and renal disease and that protection against atherosclerosis is more effectively achieved by early treatment than by late treatment, thus suggesting that early inhibition of AGE formation attenuates progression of macroangiopathy and favours development of more stable lesions.</description><subject>Age</subject><subject>Animals</subject><subject>Aorta - drug effects</subject><subject>Aorta - metabolism</subject><subject>Aorta - pathology</subject><subject>Aortic Diseases - blood</subject><subject>Aortic Diseases - diagnosis</subject><subject>Aortic Diseases - genetics</subject><subject>Aortic Diseases - prevention &amp; control</subject><subject>Apolipoproteins E - deficiency</subject><subject>Apolipoproteins E - genetics</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis - blood</subject><subject>Atherosclerosis - diagnosis</subject><subject>Atherosclerosis - genetics</subject><subject>Atherosclerosis - prevention &amp; control</subject><subject>Biomarkers - blood</subject><subject>Carnosine - analogs &amp; derivatives</subject><subject>Carnosine - pharmacology</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Experimental - blood</subject><subject>Diabetes Mellitus, Experimental - diagnosis</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetes Mellitus, Experimental - genetics</subject><subject>Diabetic Angiopathies - blood</subject><subject>Diabetic Angiopathies - diagnosis</subject><subject>Diabetic Angiopathies - genetics</subject><subject>Diabetic Angiopathies - prevention &amp; control</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - diagnosis</subject><subject>Diabetic Nephropathies - genetics</subject><subject>Diabetic Nephropathies - prevention &amp; control</subject><subject>Disease Progression</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Glycation End Products, Advanced - antagonists &amp; inhibitors</subject><subject>Glycation End Products, Advanced - blood</subject><subject>Human Physiology</subject><subject>Hyperglycemia</subject><subject>Internal Medicine</subject><subject>Kidney - drug effects</subject><subject>Kidney - metabolism</subject><subject>Kidney - pathology</subject><subject>Kidney diseases</subject><subject>Laboratory animals</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metabolic Diseases</subject><subject>Metabolism</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Plaque, Atherosclerotic</subject><subject>Signal Transduction - drug effects</subject><subject>Smooth muscle</subject><subject>Time Factors</subject><issn>0012-186X</issn><issn>1432-0428</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kcGKFDEQhoMo7uzoA3iRgBcv0aSTTme8LYu6woIeFLw11UllN0smPSbdC_1iPp_pmVVE8JJA_q_-qtRPyAvB3wjOu7eFc9G0jAvFpNId04_IRijZMK4a85hsVpkJo7-fkfNS7jjnslX6KTlrWtWJbqc25OeXPE5opzAm6vO4py7AgBMWFpKbLToK0y3msdi4nqFQSI5mTBArWhAK0mGhjlnIqeoJ2WinJWKZML-j6H01L3T0FCHHhd4XGmFCGtJtGMKxbdXA3UNam93ExcLxFZNjhzzWGWp5SPTiMCJLc4x0Hyw-I088xILPH-4t-fbh_dfLK3b9-eOny4trZpVpJ9Z5oTQK6IzfDQASrbHWt61ELb20jTADgrXCeNcoI73znTLWA6BttGkbuSWvT751lB9z_VS_D8VijJBwnEsvtBZS8l3d-pa8-ge9G-dc93SkuDFadaZS4kTZus2S0feHHPaQl17wfg21P4Xa11D7NdRe15qXD87zsEf3p-J3ihVoTkCpUrrB_Ffr_7r-AoYAsbM</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Menini, Stefano</creator><creator>Iacobini, Carla</creator><creator>Ricci, Carlo</creator><creator>Fantauzzi, Claudia Blasetti</creator><creator>Pugliese, Giuseppe</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice</title><author>Menini, Stefano ; Iacobini, Carla ; Ricci, Carlo ; Fantauzzi, Claudia Blasetti ; Pugliese, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Age</topic><topic>Animals</topic><topic>Aorta - drug effects</topic><topic>Aorta - metabolism</topic><topic>Aorta - pathology</topic><topic>Aortic Diseases - blood</topic><topic>Aortic Diseases - diagnosis</topic><topic>Aortic Diseases - genetics</topic><topic>Aortic Diseases - prevention &amp; control</topic><topic>Apolipoproteins E - deficiency</topic><topic>Apolipoproteins E - genetics</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis - blood</topic><topic>Atherosclerosis - diagnosis</topic><topic>Atherosclerosis - genetics</topic><topic>Atherosclerosis - prevention &amp; control</topic><topic>Biomarkers - blood</topic><topic>Carnosine - analogs &amp; derivatives</topic><topic>Carnosine - pharmacology</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Experimental - blood</topic><topic>Diabetes Mellitus, Experimental - diagnosis</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetes Mellitus, Experimental - genetics</topic><topic>Diabetic Angiopathies - blood</topic><topic>Diabetic Angiopathies - diagnosis</topic><topic>Diabetic Angiopathies - genetics</topic><topic>Diabetic Angiopathies - prevention &amp; control</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - diagnosis</topic><topic>Diabetic Nephropathies - genetics</topic><topic>Diabetic Nephropathies - prevention &amp; control</topic><topic>Disease Progression</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Glycation End Products, Advanced - antagonists &amp; inhibitors</topic><topic>Glycation End Products, Advanced - blood</topic><topic>Human Physiology</topic><topic>Hyperglycemia</topic><topic>Internal Medicine</topic><topic>Kidney - drug effects</topic><topic>Kidney - metabolism</topic><topic>Kidney - pathology</topic><topic>Kidney diseases</topic><topic>Laboratory animals</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metabolic Diseases</topic><topic>Metabolism</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Plaque, Atherosclerotic</topic><topic>Signal Transduction - drug effects</topic><topic>Smooth muscle</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Menini, Stefano</creatorcontrib><creatorcontrib>Iacobini, Carla</creatorcontrib><creatorcontrib>Ricci, Carlo</creatorcontrib><creatorcontrib>Fantauzzi, Claudia Blasetti</creatorcontrib><creatorcontrib>Pugliese, Giuseppe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Menini, Stefano</au><au>Iacobini, Carla</au><au>Ricci, Carlo</au><au>Fantauzzi, Claudia Blasetti</au><au>Pugliese, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice</atitle><jtitle>Diabetologia</jtitle><stitle>Diabetologia</stitle><addtitle>Diabetologia</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>58</volume><issue>4</issue><spage>845</spage><epage>853</epage><pages>845-853</pages><issn>0012-186X</issn><eissn>1432-0428</eissn><abstract>Aims/hypothesis AGEs are involved in diabetic complications and might be responsible for the phenomenon of ‘hyperglycaemic memory’. d -Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in Apoe -null mice. This study aimed to verify the protective effect of DCO in atherosclerosis and renal disease induced by experimental diabetes and to discover whether reduction of AGE formation by early vs late DCO treatment provides better macro and microvascular protection. Methods Apoe -null mice were rendered diabetic by streptozotocin and were left untreated or were treated with DCO for 20 weeks (DCO-Extended), from week 1 to 11 (DCO-Early) or from week 9 to 19 (DCO-Late). Non-diabetic Apoe -null mice served as controls. Aortic and renal lesions were evaluated by morphometry and protein and gene expression of disease markers were assessed by immunohistochemistry and real-time PCR. Results DCO-Extended treatment produced a more stable plaque phenotype by markedly attenuating diabetes-induced increases in lesion size, necrotic core area and plaque content of Nε-carboxymethyllysine, levels of apoptotic cells and markers of inflammation and oxidative stress and also reductions in collagen and smooth muscle cells. DCO treatment for 11 weeks afforded partial protection and this was significantly better in DCO-Early mice than in DCO-Late mice. Renal disease was attenuated in DCO-Extended mice and to a lesser extent in those treated for 11 weeks, with no significant difference between DCO-Early mice and DCO-Late mice. Conclusions/interpretation These data show that DCO protects mice from diabetes-induced vascular and renal disease and that protection against atherosclerosis is more effectively achieved by early treatment than by late treatment, thus suggesting that early inhibition of AGE formation attenuates progression of macroangiopathy and favours development of more stable lesions.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25471794</pmid><doi>10.1007/s00125-014-3467-6</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0012-186X
ispartof Diabetologia, 2015-04, Vol.58 (4), p.845-853
issn 0012-186X
1432-0428
language eng
recordid cdi_proquest_miscellaneous_1661330914
source Springer Nature
subjects Age
Animals
Aorta - drug effects
Aorta - metabolism
Aorta - pathology
Aortic Diseases - blood
Aortic Diseases - diagnosis
Aortic Diseases - genetics
Aortic Diseases - prevention & control
Apolipoproteins E - deficiency
Apolipoproteins E - genetics
Atherosclerosis
Atherosclerosis - blood
Atherosclerosis - diagnosis
Atherosclerosis - genetics
Atherosclerosis - prevention & control
Biomarkers - blood
Carnosine - analogs & derivatives
Carnosine - pharmacology
Diabetes
Diabetes Mellitus, Experimental - blood
Diabetes Mellitus, Experimental - diagnosis
Diabetes Mellitus, Experimental - drug therapy
Diabetes Mellitus, Experimental - genetics
Diabetic Angiopathies - blood
Diabetic Angiopathies - diagnosis
Diabetic Angiopathies - genetics
Diabetic Angiopathies - prevention & control
Diabetic Nephropathies - blood
Diabetic Nephropathies - diagnosis
Diabetic Nephropathies - genetics
Diabetic Nephropathies - prevention & control
Disease Progression
Epidemiology
Female
Glycation End Products, Advanced - antagonists & inhibitors
Glycation End Products, Advanced - blood
Human Physiology
Hyperglycemia
Internal Medicine
Kidney - drug effects
Kidney - metabolism
Kidney - pathology
Kidney diseases
Laboratory animals
Medicine
Medicine & Public Health
Metabolic Diseases
Metabolism
Mice
Mice, Knockout
Plaque, Atherosclerotic
Signal Transduction - drug effects
Smooth muscle
Time Factors
title Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A48%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protection%20from%20diabetes-induced%20atherosclerosis%20and%20renal%20disease%20by%20d-carnosine-octylester:%20effects%20of%20early%20vs%20late%20inhibition%20of%20advanced%20glycation%20end-products%20in%20Apoe-null%20mice&rft.jtitle=Diabetologia&rft.au=Menini,%20Stefano&rft.date=2015-04-01&rft.volume=58&rft.issue=4&rft.spage=845&rft.epage=853&rft.pages=845-853&rft.issn=0012-186X&rft.eissn=1432-0428&rft_id=info:doi/10.1007/s00125-014-3467-6&rft_dat=%3Cproquest_cross%3E1661330914%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c485t-7f146e1a78f9baa3ec8ccf553e63f3c218beacc18fd2483fdf748cfaaec268523%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1660886478&rft_id=info:pmid/25471794&rfr_iscdi=true